New hope for lung scarring: ABBV-142 enters Mid-Stage trial

NCT ID NCT07230288

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called ABBV-142 in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and breathing problems. About 165 adults will receive either ABBV-142 or a placebo for 52 weeks to see if the drug is safe and can help preserve lung function. The trial is double-blind, meaning neither participants nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-142
What this could lead to: If successful, this could point toward a new treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong: This is an early Phase 2a study with a small sample size, so results may not confirm effectiveness. The drug is investigational and may cause side effects or fail to improve lung function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Centre d'Investigation Clinique Mauricie /ID# 277949
RECRUITING

Trois-Rivières, Quebec, G8T 7A1, Canada
China Medical University Hospital /ID# 278039
RECRUITING

Taichung, 40447, Taiwan
Christie Clinic on University /ID# 277871
RECRUITING

Champaign, Illinois, 61820, United States
Hannibal Regional Hospital /ID# 277984
RECRUITING

Hannibal, Missouri, 63401, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 278029
RECRUITING

Kaohsiung City, 807, Taiwan
Sec Clinical Research - East - Dothan - Graceland /ID# 278328
RECRUITING

Dothan, Alabama, 36305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.